uniQure

uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. UniQure are leveraging modular and validated technology platform to rapidly advance a pipeline of proprietary gene therapies to treat patients with hemophilia B, Huntington's disease, Fabry disease, spinocerebellar ataxia Type 3 and other diseases.
uniQure stock price chart
vol.
change
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

uniQure balance sheet

Report period2018 2019 2020 2021 2022Q3 23
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

uniQure cash flows

Report period2018 2019 2020 2021 2022Q3 23 TTM
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

uniQure multipliers

Report period2018 2019 2020 2021 2022Q3 23 TTM
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

uniQure profitability

Report period2018 2019 2020 2021 2022Q3 23 TTM
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
uniQure assets
uniQure cash flows

uniQure dividend policy

The company doesn't provide dividend.

uniQure shares

TickerNameTypeNominal valueISINPrice
QURE:USuniQureCommon share-NL0010696654$4.67
uniQure news
02.05.2022
UniQure's GAAP loss for 3 months of 2022 was $46.678 million, up 12.3% from $41.556 million in the previous year. Revenues increased 3.9 times to $1.792 million from $0.454 million a year earlier.
Source: {source} pictogram tools.eurolandir.com
Pictogram next
25.02.2022
UniQure's GAAP net income for 2021 was $329.589 million, compared to a loss of $125.024 million in the previous year. Revenues increased 13.96 times to $524.002 million from $37.514 million a year earlier.
Source: {source} pictogram tools.eurolandir.com
Pictogram next
25.10.2021
UniQure's GAAP loss for Q3 2021 was $36.531 million, down 32.1% from $53.775 million in the prior year. Revenue increased 11.2% to $1,989 million compared to $1,789 million a year earlier.
Source: {source} pictogram tools.eurolandir.com
Pictogram next
26.07.2021
UniQure's GAAP net income for Q2 2021 was $399.468 mln, compared to a loss of $42.551 mln in the previous year. Revenues increased 302 times to $463.868 million from $1.535 million a year earlier.
Source: {source} pictogram tools.eurolandir.com
Pictogram next
All uniQure news
General information
Company nameuniQure
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business addressPaasheuvelweg 25a Amsterdam, 1105BP Netherlands
Websitewww.uniqure.com
Information disclosurewww.sec.gov